Navigation Links
Valeant Pharmaceuticals Provides Update to Recent Event
Date:4/4/2013

MONTREAL, April 4, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today responded to a generic approval for Zovirax® ointment.

"Yesterday, Mylan announced they had received approval of a generic Zovirax® ointment," stated J. Michael Pearson .  "While the timing of a generic approval was always uncertain, this was not unforeseen and we were prepared for its eventuality. In response to the new generic approval, we will be launching an authorized generic of Zovirax® ointment today.  Valeant's business model is based on diversification which allows us to better balance sudden events such as this. 

"As we did not include this event in our original budget expectations, we expect this isolated event could impact our Cash EPS by $0.30 to $0.40 in 2013," continued Pearson.  "But there are other actions, such as several product acquisitions, the repricing of our term loan debt and continued operational performance that have occurred since we provided financial guidance in January, and we believe that these activities will mitigate the impact of the genericization of Zovirax® ointment.  We continue to expect once again to deliver outstanding performance in 2013 and we will provide an update to our 2013 guidance on our first quarter financial results conference call in May."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Statements

This press release contains forward-looking statements regarding, among other things, the ability of our business model to deal with unexpected events, the launch of our authorized generic of Zovirax ointment, the financial impact of the genericization of Zovirax ointment, and our 2013 performance.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to the market acceptance of our authorized generic Zovirax ointment, the impact of the genericization of Zovirax ointment and other risks and uncertainties, including those detailed from time to time in Valeant's periodic reports filed with the Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators ("CSA"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "RISK FACTORS" in Valeant's annual reports on Form 10-K for the year ended December 31, 2012, which have been filed with the SEC and the CSA. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause Valeant's actual results to differ materially from expected and historical results. Valeant assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
2. Valeant Pharmaceuticals Announces Private Exchange Offer
3. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
4. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
5. Valeant Completes Acquisition Of Natur Produkt In Russia
6. Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013
7. Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call
8. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
9. Valeant Pharmaceuticals Announces New Management Appointments
10. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
11. Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Injectables Market and Increasing Usage of Complex Biologics during the Forecast ... ... USD 20 Billion in 2015 to around USD 26 Billion by ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental are ... dental fear and require sedation to receive dental care. The doctors offer three treatment ... from hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall Centre ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients ... that achieves results in a fraction of the time as traditional braces – ... Significance Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring reignites vigilance ... research related to Zika virus during pregnancy, as well as other prenatal exposures ... science. , The Teratology Society is an international and multidisciplinary ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving multi-billion dollar ... shops –can’t help but be heartened by the industry’s current surge. But another thing ... as “skunk smell.” At last they can simply, safely and effectively end their ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading provider of ... management module. Using this new feature, sleep physicians can now predict the likelihood ... positive airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The ...
Breaking Medicine News(10 mins):